Contrasting Pressure Biosciences (PBIO) & Its Peers
Pressure Biosciences (OTCMKTS: PBIO) is one of 25 public companies in the “Analytical instruments” industry, but how does it weigh in compared to its competitors? We will compare Pressure Biosciences to related companies based on the strength of its earnings, valuation, analyst recommendations, institutional ownership, profitability, risk and dividends.
This is a summary of current ratings and price targets for Pressure Biosciences and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pressure Biosciences Competitors||183||917||1284||65||2.50|
This table compares Pressure Biosciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pressure Biosciences Competitors||-212.02%||-25.29%||-11.33%|
Volatility & Risk
Pressure Biosciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Pressure Biosciences’ competitors have a beta of 1.45, suggesting that their average stock price is 45% more volatile than the S&P 500.
Insider and Institutional Ownership
62.4% of shares of all “Analytical instruments” companies are owned by institutional investors. 15.9% of Pressure Biosciences shares are owned by company insiders. Comparatively, 13.5% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Pressure Biosciences and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Pressure Biosciences||$2.46 million||-$9.70 million||-0.16|
|Pressure Biosciences Competitors||$1.14 billion||$146.92 million||11.84|
Pressure Biosciences’ competitors have higher revenue and earnings than Pressure Biosciences. Pressure Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Pressure Biosciences competitors beat Pressure Biosciences on 8 of the 10 factors compared.
About Pressure Biosciences
Pressure BioSciences, Inc. develops pressure cycling technology (PCT) solutions. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler NEP3229, HUB440, HUB880, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT-MicroCaps, PCT-Micro-Pestle, PULSE Tubes, and BaroFlex 8-well Processing Strips, as well as application specific kits. Pressure BioSciences, Inc. serves researchers at academic laboratories; government agencies; and biotechnology, pharmaceutical, and other life sciences institutions in the United States, Europe, and Asia. Pressure BioSciences, Inc. has a collaboration with NutraFuels, Inc. for the development of water-soluble Nanoemulsion-based nutraceuticals. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.
Receive News & Ratings for Pressure Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pressure Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.